Systemic lupus erythematosus in the elderly

Autoimmunity Reviews

Volumn 7, Issue 3, 2008, Pages 235-239

  Rovensky J ^a   Tuchynova A ^a  

^a NATIONAL INSTITUTE OF RHEUMATIC DISEASES   (Slovakia)

Author keywords

Clinical picture; Late onset; SLE

Indexed keywords

ACEBUTOLOL; AZATHIOPRINE; CARBAMAZEPINE; CHLOROQUINE; CHLORPROMAZINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HYDRALAZINE; HYDROXYCHLOROQUINE; ISONIAZID; LA ANTIBODY; METHYLDOPA; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PROCAINAMIDE; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SALAZOSULFAPYRIDINE;

AUTOIMMUNITY; AVASCULAR NECROSIS; CATARACT; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DRUG DOSE TITRATION; FLUID RETENTION; GERIATRIC PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOCOMPLEMENTEMIA; HYPOKALEMIA; INFECTION; INFLAMMATION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; ONSET AGE; OSTEOARTHRITIS; OSTEOPOROSIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT;

AGE OF ONSET; AGED; ANTI-INFLAMMATORY AGENTS; AUTOANTIBODIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RHEUMATOID FACTOR;

EID: 37749004491     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2007.11.014     Document Type: Review

References (41)

1. Tsokos G.C. Overview of cellular immune function in systemic lupus erythematosus. In: Lahita G. (Ed). Systemic lupus erythematosus. 4th ed. (2004), Elsevier 29-92
2. Manoussakis M.N., Tzioufas A.G., Silis M.P., Pange P.J., Goudevenos J., and Moutsopoulos H.M. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 69 3 (Sep 1987) 557-565
3. Kammer G.M., and Mishra N. Systemic lupus erythematosus in the elderly. Rheum Dis Clin N Amer 26 (2000) 475-492
4. Song L., Kim Y.H., Chopra R.K., Proust J.J., Nagel J.E., Nordin A.A., et al. Age-related effects in T cell activation and proliferation. Exp Gerontol. 28 4-5 (Jul--Oct 1993) 313-321
5. Krabbe K.S., Pedersen M., and Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 39 (2004) 687-699
6. Gladman D.D., and Urowitz M.B. Connective tissue disorders. Systemic lupus erythematosus. Clinical features. In: Klippel J.H., and Dieppe P.A. (Eds). Rheumatology (1994), Mosby, London 6.2.1.-20
7. Maddison P.J. Systemic lupus erythematosus in the elderly. J Rheumatol 14 suppl 13 (1987) 182-187
8. Formiga F., Moga I., Pac M., Mitjavila F., Rivera A., and Rujol R. Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI. SLE Disease Activity Index. Lupus 8 6 (1999) 462-465
9. Pu S.J., Luo S.F., Wu Y.J., Chong H.S., and Ho H.H. The clinical features and prognosis of lupus with disease onset at age 65 and older. Lupus 9 2 (2000) 96-100
10. Weitzel KW. Treatment of lupus erythematosus. www.cop.ufl.edu/safezone/root/programs/cepm/Lupus/Article.pdf. Formát súboru PDF/Adobe Acrobat-HTML verzia.
11. Baker S.B., Rovira J.R., Campion E.W., and Mills J.A. Late onset systemic lupus erythematosus. Am J Med 66 5 (1979 May) 727-732
12. Padovan M., Govoni M., Castellino G., Rizzo N., Fotinidi M., and Trotta F. Late onset systemic lupus erythematosus: no substantial differences using different cut-off ages. Rheumatol Int 27 8 (Jun 2007) 735-741
13. Erratum in:. Arthritis Rheum. 54 7 (July 2006) 2320
14. Bertoli A.M., Alarcón G.S., Calvo-Alén J., Fernández M., Vilá L.M., Reveille J.D., and LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease. Arthritis Rheum 54 5 (May 2006) 1580-1587
15. Catoggio L.J., Skinner R.P., Smith G., and Maddison P.J. Systemic lupus erythematosus in the elderly: clinical and serological characteristics. J Rheumatol 11 2 (Apr 1984) 175-181
16. Ramos-Casals M., Garcia-Carraso M., Brito M.P., López-Soto A., and Font J. Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus 12 5 (2003) 341-355
17. Wilson H.A., Hamilton M.E., Spyker D.A., et al. Age influences the clinical and serological expression of systemic lupus erythematosus. Arthritis Rheum 24 (1981) 1230-1235
18. Tuchyňová A., Rovenský J., and Lukáč J. Systémový lupus erythematosus vo vyššom veku: retrospektívna štúdia. Česká revmatologie 6 (1998) 123-126
19. Mak S.K., Lam E.K.M., and Wong A.K.M. Clinical profile of patients with late-onset SLE: not a benign subgroup. Lupus 7 (1998) 23-28
20. Maddison P., Farewell V., Isenberg D., et al. The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol 29 (2002) 913-917
21. Belostocki K.B., and Paget S.A. Inflammatory rheumatologic disorders in the elderly. Postgrad Med 111 (2002) 72-83
22. Cervera K., Khamashta M.A., Font J., et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine 72 (1993) 113-124
23. Ward M.M., and Polisson R.P. A meta-analysis of the clinical manifestation of older-onset systemic lupus erythematosus. Arthritis Rheum 32 (1989) 1226-1232
24. Boddaert J., Huong D.L., Amoura Z., et al. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore) 83 (2004) 348-359
25. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 25 (1982) 1271-1277
26. Rovenský J., Lukáč J., Cebecauer L., et al. Lupus erythematosus indukovaný liekmi. In: Rovenský J., and Pavelka K. (Eds). Klinická revmatologie (2000), Martin, Osveta 301-305
27. Alper C.A., Husain Z., Larsen C.E., Dubey D.P., Stein R., Day C., et al. Incomplete penetrance of susceptibility genes for MHC-determined immunoglobulin deficiencies in monozygotic twins discordant for type 1 diabetes. J Autoimmun 27 2 (Sep 2006) 89-95
28. Ambrozic A., Cucnik S., Tomsic N., Urbanija J., Lokar M., Babnik B., Rozman B., et al. Interaction of giant phospholipid vesicles containing cardiolipin and cholesterol with beta2-glycoprotein-I and anti-beta2-glycoprotein-I antibodies. Autoimmun Rev 6 1 (Nov 2006) 10-15
29. Aoki C.A., Roifman C.M., Lian Z.X., Bowlus C.L., Norman G.L., Shoenfeld Y., et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun 27 1 (Aug 2006) 50-53
30. Bozic B., Cucnik S., Kveder T., and Rozman B. Changes in avidity and specificity of IgG during electro-oxidation. Relevance of binding of antibodies to beta2-GPI. Autoimmun Rev 6 1 (Nov 2006) 28-32
31. Deshmukh U.S., Bagavant H., and Fu S.M. Role of anti-DNA antibodies in the pathogenesis of lupus nephritis. Autoimmun Rev 5 (2006) 414-418
32. Duan B., and Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev 5 (2006) 403-408
33. Gilliam L.K., Jensen R.A., Yang P., Weigle D.S., Greenbaum C.J., and Pihoker C. Evaluation of leptin levels in subjects at risk for type 1 diabetes. J Autoimmun 26 2)(Mar (2006) 133-137
34. Holzer U., Rieck M., and Buckner J.H. Lineage and signal strength determine the inhibitory effect of transforming growth factor beta1 (TGF-beta1) on human antigen-specific Th1 and Th2 memory cells. J Autoimmun 26 (2006) 241-251
35. Koutouzov S., Mathian A., and Dalloul A. Type-I interferons and systemic lupus erythematosus. Autoimmun Rev 5 (2006) 554-562
36. Moritoki Y., Lian Z.X., Ohsugi Y., Ueno Y., and Gershwin M.E. Links B cells and autoimmune liver diseases. Autoimmun Rev 5 7 (Aug 2006) 449-457
37. Rieger R., Leung P.S., Jeddeloh M.R., Kurth M.J., Nantz M.H., Lam K.S., et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun 27 1 (Aug 2006) 7-16
38. Rosloniec E.F., Brandstetter T., Leyer S., Schwaiger F.W., and Nagy Z.A. Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models. J Autoimmun 27 3 (Nov 2006) 182-195
39. Staub H.L., Franck M., Ranzolin A., Norman G.L., Iverson G.M., and von Mühlen C.A. IgA antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmun Rev 6 2 (Dec 2006) 104-106
40. Strous R.D., and Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 27 (2006) 71-80
41. Zlacka D., Vavrincova P., Hien Nguyen T.T., and Hromadnikova I. Frequency of anti-hsp60, -65 and -70 antibodies in sera of patients with juvenile idiopathic arthritis. J Autoimmun 27 2 (Sep 2006) 81-88